The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
暂无分享,去创建一个
Christophe Béroud | Hanns Lochmüller | Petr Brabec | Clemens Bloetzer | Rosário Santos | Kyriaki Kekou | Leanne Lamont | Svetlana Artemieva | Lawrence Korngut | Craig Campbell | Richard Roxburgh | Volker Straub | Kevin M Flanigan | Dina Vojinovic | Manuel Posada | K. Bushby | K. Flanigan | C. Béroud | D. Vojinović | Hanns Lochmüller | M. Bellgard | M. Posada | H. Dawkins | D. Salgado | P. Jeannet | M. Rodrigues | R. Roxburgh | C. Campbell | H. Topaloglu | V. Karcagi | M. Walter | E. Gallardo | V. Straub | S. Monges | J. Zimowski | P. Brabec | J. Díaz-Manera | N. Barišić | Rosário Santos | F. Buccella | V. Rašić | Janusz Zimowski | Anna Lusakowska | Vedrana Milic Rasic | Veronika Karcagi | Marta Garami | Soledad Monges | Teodora Chamova | Velina Guergueltcheva | Miriam Rodrigues | Hugh Dawkins | Jaana Lahdetie | Pierre-Yves Jeannet | David Salgado | Jan Kirschner | Kate Bushby | Jan Verschuuren | Holly L Peay | K. Kosma | J. Kirschner | C. Bloetzer | Catherine L Bladen | Maria E Foncuberta | Konstantina Kosma | Anna J Roy | Sophelia Chan | Yi Dai | Jen Wang | Nina Barišić | Maggie C Walter | Olivia Schreiber-Katz | Venkatarman Viswanathan | Farhad Bayat | Filippo Buccella | En Kimura | Zaïda Koeks | Janneke C van den Bergen | Anna Kostera-Pruszczyk | Elena Neagu | Franziska Joncourt | Jordi Díaz-Manera | Eduard Gallardo | A Ayşe Karaduman | Haluk Topaloğlu | Rasha El Sherif | Angela Stringer | Andriy V Shatillo | Ann S Martin | Matthew I Bellgard | Annemieke Aartsma-Rus | L. Korngut | H. Peay | A. Karaduman | A. Roy | F. Joncourt | S. Chan | V. Guergueltcheva | Olivia Schreiber-Katz | A. Kostera-Pruszczyk | A. Shatillo | K. Kekou | J. Verschuuren | E. Kimura | M. Foncuberta | E. Neagu | T. Chamova | Z. Koeks | Ann S. Martin | R. el Sherif | A. Lusakowska | C. Bladen | Leanne Lamont | J. C. van den Bergen | A. Stringer | Farhad Bayat | A. Aartsma-Rus | J. Lahdetie | S. Artemieva | V. Viswanathan | Y. Dai | M. Garami | Jen Wang | O. Schreiber-Katz | H. Topaloğlu
[1] Thomas W Prior,et al. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. , 2005, The Journal of molecular diagnostics : JMD.
[2] L. Kunkel,et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.
[3] M. Vihinen,et al. Recommendations for locus‐specific databases and their curation , 2008 .
[4] I. Graham,et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. , 2007, Human gene therapy.
[5] Domenica Taruscio,et al. The TREAT‐NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia , 2013, Human mutation.
[6] R. Waterston,et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. , 1988, The New England journal of medicine.
[7] Livija Medne,et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.
[8] G. van Ommen,et al. Advances in therapeutic RNA-targeting. , 2013, New biotechnology.
[9] K. Bushby,et al. Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations. , 2009, Advances in experimental medicine and biology.
[10] P. Iversen,et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD , 2006, Gene Therapy.
[11] G. van Ommen,et al. Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.
[12] Meenal Patel,et al. PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.
[13] Y. Takeshima,et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient , 2001, Brain and Development.
[14] K. Bushby,et al. Collaborating to bring new therapies to the patient--the TREAT-NMD model. , 2009, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[15] Thierry Soussi,et al. UMD (Universal Mutation Database): 2005 update , 2005, Human mutation.
[16] S. Peltz,et al. Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers , 2007, Journal of clinical pharmacology.
[17] Christophe Béroud,et al. Genotype–phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD–DMD database: a model of nationwide knowledgebase , 2009, Human mutation.
[18] Nathalie Jette,et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy , 2014, Neuromuscular Disorders.
[19] G. van Ommen,et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.
[20] Y. Takeshima,et al. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. , 2004, Human gene therapy.
[21] Christophe Béroud,et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.
[22] F. Baas,et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. , 2003, Human molecular genetics.
[23] K. Flanigan,et al. Sequence specificity of aminoglycoside‐induced stop codon readthrough: Potential implications for treatment of Duchenne muscular dystrophy , 2000, Annals of neurology.
[24] R. Jones,et al. To be Therapeutic. , 1967 .
[25] N. Laing. Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophy. , 1993, Molecular and cell biology of human diseases series.
[26] E. Hoffman,et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. , 2012, Physical medicine and rehabilitation clinics of North America.
[27] M Krawczak,et al. Neighboring-nucleotide effects on the rates of germ-line single-base-pair substitution in human genes. , 1998, American journal of human genetics.
[28] G. van Ommen,et al. The therapeutic potential of antisense-mediated exon skipping. , 2008, Current opinion in molecular therapeutics.
[29] L. Kunkel,et al. The structural and functional diversity of dystrophin , 1993, Nature Genetics.
[30] G. van Ommen,et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.
[31] K. Fischbeck,et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations , 2001, Annals of neurology.
[32] R. Finkel,et al. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy , 2008, Annals of neurology.